Docket No. 2026-4124

PATENT

(Figure 1; SEQ ID NO: 2) or the [#]gp100 amino acid sequence (Figure 5A; SEQ ID NO: 27), said peptide being [reactive to] recognized by tumor infiltrating lymphocytes (TIL).

57. (Amended) A recombinant expression vector comprising [?] at least one nucleic acid sequence of claim 36 linked to an expression control sequence.

Please add the following new claims:

As isolated nucleic acid sequence encoding a MART-1 (melanoma antigen recognized by T-cells-1) protein and having the nucleic acid sequence selected from the group consisting of (a) a nucleic acid sequence shown in Figure 1 (SEQ ID NO:1); (b) an allelic variation of the nucleic acid sequence shown in Figure 1 (SEQ ID NO:1); and (c) a homolog of the nucleic acid sequence shown in Figure 1 (SEQ ID NO:1), wherein the nucleic acid sequences of (a) - (c) encode a melanoma antigen.

The nucleic acid of claim 58, wherein the nucleic acid sequence is the nucleic acid sequence shown in Figure 1 (SEQ ID NO:1).

60. The nucleic acid sequence of claim 58 wherein the nucleic acid sequence is an allelic variation of the nucleic acid sequence shown in Figure 1 (SEQ ID NO:1).

61. The nucleic acid sequence claim 58, wherein the nucleic acid sequence is a homology of the nucleic acid sequence shown in Figure 1 (SEQ ID NO:1).

An isolated nucleic acid sequence encoding a MART-1 (melanoma antigen recognized by T-cells-1) protein, wherein the nucleic acid sequence encodes a MART-1 protein shown in Figure 1 (SEQ ID NO:2).

105

- 2 -

Docket No. 2026-4124

PATENT

An isolated nucleic acid sequence encoding for a MART-1 (melanoma antigen recognized by T-cells) protein as set forth in Figure 1 (SEQ ID NO:2), wherein said nucleic acid sequence hybridizes to the MART-1 nucleic acid sequence set forth in Figure 1 (SEQ ID NO:1) under stringent conditions.

The nucleic acid sequence of claim 56, wherein said peptide is a MART-1 peptide having the amino acid sequence AAGIGILTV (SEQ ID NO: 4), EAAGIGILTV (SEQ ID NO: 17) or AAGIGILTVI (SEQ ID NO: 18).

65. The nucleic acid sequence of claim 56, wherein said peptide is a gp100 peptide having the amino acid sequence LLDGTATLRL (SEQ ID NO: 31), VLYRYGSFSV (SEQ ID NO: 32), VLKRCLLHL (SEQ ID NO: 34), ALDGGNKHFL (SEQ ID NO: 33), VLPSPACQLV (SEQ ID NO: 35), SLADTNSLAV (SEQ ID NO: 36), SVSVSQLRA (SEQ ID NO: 37), YLEPGPVTA (SEQ ID NO: 38) or LNVSLADTN (SEQ ID NO: 39).

REMARKS

Claims 1-57 were pending in this application. Claims 1-5 and 56-57 stand rejected and claims 6-55 are withdrawn from consideration. Claims 1-5 have been cancelled without prejudice or disclaimer, and new claims 58-65 have been added. Support for the amendments and new claims may be found throughout the specification. For example, support for new claims 58-62 may be found in original claims 1-5, page 9, lines 13-34, page 17, lines 12-30; for claim 63 at page 13, lines 27-36, pages 14-16, page 17, lines 1-30; page 46, lines 30-36, page 47, lines 1-31; for claim 64 at page 8, lines 12-20, page 20, lines 1-20;

Cart